+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 0 - 9Years
All Genders
ID06302348

Long-Term Evaluation of Sepiapterin for Neurocognitive Outcomes in Children with Phenylketonuria

Led by PTC Therapeutics · Updated on 2026-10-23

56

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term effect of sepiapterin on preserving brain function in children with Phenylketonuria PKU when treatment begins in early childhood. The study includes children up to 9 years old and focuses on neurocognitive outcomes over several years. The trial has two parts Part 1 is an open-label test to see how participants respond to sepiapterin, and Part 2 is an open-label treatment period. Participants will take age- and weight-adjusted doses of sepiapterin powder orally once daily for up to 6 years. The powder will be mixed with water or apple juice before administration. During the study, children will be regularly assessed with intelligence tests such as the Wechsler Preschool and Primary Scale of Intelligence and the Wechsler Intelligence Scale for Children. Quality of life and blood phenylalanine levels will also be monitored. The researchers will track changes from baseline over 2 to 6 years to evaluate treatment effects. Safety and adherence will be overseen throughout the duration until the study concludes in 2031.

CONDITIONS

Brief Title

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

Research Team

P

Patient Advocacy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here